Literature DB >> 25217178

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study.

Sune F Nielsen1, Børge G Nordestgaard2.   

Abstract

BACKGROUND: The role of statins in the development of microvascular disease in patients with diabetes is unknown. We tested the hypothesis that statin use increases the risk of diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, and gangrene of the foot in individuals with diabetes.
METHODS: We identified all patients living in Denmark who were aged 40 years or older and were diagnosed with incident diabetes between Jan 1, 1996, and Dec 31, 2009. We obtained patients' data from the Danish Patient Registry and information on drug use from the Danish Registry of Medicinal Product Statistics. We randomly selected 15,679 individuals from the database who had used statins regularly until their diagnosis of diabetes (statin users) and matched them in a 1:3 ratio with 47,037 individuals who had never used statins before diagnosis (non-statin users). Our primary outcome was to compare the cumulative incidence of diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, or gangrene of the foot in statin users versus non-statin users. We analysed data with Cox regression models, adjusted for covariates including sex, age at diabetes diagnosis, and method of diabetes diagnosis. To address potential biases between statin users and non-statin users, we made adjustments to our analysis with a propensity score and with other factors. Median follow-up was 2·7 years (range 0-13).
FINDINGS: During 215,725 person-years of follow-up, 2866 patients developed diabetic retinopathy, 1406 developed diabetic neuropathy, 1248 developed diabetic nephropathy, and 2392 developed gangrene of the foot. Compared with non-statin users, statin users had a lower cumulative incidence of diabetic retinopathy (hazard ratio 0·60, 95% CI 0·54-0·66; p<0·0001), diabetic neuropathy (0·66, 0·57-0·75; p<0·0001), and gangrene of the foot (0·88, 0·80-0·97; p=0·010), but not diabetic nephropathy (0·97, 0·85-1·10; p=0·62). These results were similar after adjusting for the competing risk of death, after matching for a propensity score, after adjusting for visits to a family doctor, and by stratification on covariates. The corresponding multivariable adjusted hazard ratio for risk of diabetes in the total population was 1·17 (95% CI 1·14-1·21; p<0·0001).
INTERPRETATION: Use of statins before diagnosis of incident diabetes was not associated with an increased risk of microvascular disease. Whether statins are protective against some forms of microvascular disease-a possibility raised by these data-will need to be addressed in other studies similar to ours, in mendelian randomisation studies, and preferably in randomised controlled trials. FUNDING: Herlev Hospital, Copenhagen University Hospital.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217178     DOI: 10.1016/S2213-8587(14)70173-1

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  30 in total

1.  Diabetes: statins for microvascular complications-all but the kidney.

Authors:  Kumar Sharma; Loki Natarajan
Journal:  Nat Rev Nephrol       Date:  2014-11-04       Impact factor: 28.314

Review 2.  Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines.

Authors:  Seth S Martin; Laurence S Sperling; Michael J Blaha; Peter W F Wilson; Ty J Gluckman; Roger S Blumenthal; Neil J Stone
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

3.  Effects of statins on the kidneys in patients with type 2 diabetes.

Authors:  Ko Hanai; Tetsuya Babazono; Yasuko Uchigata
Journal:  Clin Exp Nephrol       Date:  2016-09-15       Impact factor: 2.801

Review 4.  Diabetes Secondary to Treatment with Statins.

Authors:  Markku Laakso; Johanna Kuusisto
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

Review 5.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.

Authors:  Gordon Sloan; Dinesh Selvarajah; Solomon Tesfaye
Journal:  Nat Rev Endocrinol       Date:  2021-05-28       Impact factor: 43.330

6.  Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013.

Authors:  Toke de Koning Svendsen; Peter Nørregaard Hansen; Luis Alberto García Rodríguez; Lene Andersen; Jesper Hallas; Søren Hein Sindrup; David Gaist
Journal:  Br J Clin Pharmacol       Date:  2017-05-11       Impact factor: 4.335

Review 7.  'Statins in retinal disease'.

Authors:  Ahmed Al-Janabi; Sue Lightman; Oren Tomkins-Netzer
Journal:  Eye (Lond)       Date:  2018-03-20       Impact factor: 3.775

8.  Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults.

Authors:  Ishak Mansi; Christopher R Frei; Chen-Pin Wang; Eric M Mortensen
Journal:  J Gen Intern Med       Date:  2015-04-28       Impact factor: 5.128

Review 9.  Statin use in prediabetic patients: rationale and results to date.

Authors:  Anastazia Kei; Evangelos C Rizos; Moses Elisaf
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

10.  Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review.

Authors:  Rui Shi; Lei Zhao; Feng Wang; Fen Liu; Zhuo Chen; Rong Li; Yang Liu; Rong Lin
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.